In 2009, the global Osteoporosis drug market was worth USD 6.8 billion, with
Bisphosphonate class of drugs leading the market. In the overall
Bisphosphonate, ibandronate (Bonviva/Boniva; Roche) and zoledronate
(Aclasta/Zometa; Novartis) accounted largest share in class, respectively, and
showed an average sales growth rate of about of 20% in the past 2 years.
Amgen's Denosumab is the recent entrant to the Osteoporosis treatment market,
following its approval from the U.S. and European Union (also approved for
bone loss associated with prostate cancer). Denosumab is expected to compete
directly with the Bisphosphonate drug class. However, initial uptake of
Denosumab is likely to be as second-line therapy, mostly in patients who are
intolerant to Bisphosphonate. In addition to the treatment of Osteoporosis,
there is substantial potential for Denosumab for treating bone loss in
patients with cancer. Denosumab market is expected to reach USD 3.8 billion in
Our research indicates that the Osteoporosis drug pipeline is going strong
with various phases of clinical development. Phase III has first-in-class
products such as odanacatib, which possess a novel mechanism of action to
combat Osteoporosis. Aprela is another drug in the stage of development.
The Chinese Osteoporosis drug Industry is expected to grow at a CAGR of 13.5%
from 2010 to 2015. Increased prevalence of Osteoporosis among Chinese female
population is the principal growth driver of the Osteoporosis drug Industry.
The other key growth drivers for Chinese Osteoporosis market include
increasing elderly aged population, rising living standards of the Chinese
people and increasing awareness and bone health education. Geographical
analysis of Chinese Osteoporosis drug market shows that there is a huge growth
potential for Osteoporosis drug in many cities including Shanghai, Beijing,
Guangzhou, and Hangzhou.
To gain a competitive advantage, market players should develop
cost-competitive drugs with easy dosage pattern, which promote bone building
effectively. Large numbers of patients are unable to comply with the strict
dosage schedule of traditional Osteoporosis drugs. Further research and
development can address the unmet need by coming up with drugs that have a
convenient dosage schedule with better efficacy and safety compared to
traditional treatment of Osteoporosis.
After 2012, the Parathyroid Hormone and SERM Osteoporosis drug class market is
expected to decline because of anticipated growth of Prolia (Denosumab), which
will largely affect other drugs' market share.
Scope and Overview
The objective of the study on "Global and China Osteoporosis Drug Industry
Analysis and Forecast (2009 - 2015)" is to gain detailed market insights for
key Osteoporosis drugs market segments. The market is analyzed on the basis of
growth trends, ongoing developments, market penetration and revenue share. The
report also covers the strategies followed by "Osteoporosis Drugs Market"
Segmentation & Analysis
The report segments and analyzes the "Osteoporosis Drugs Market" on the basis
of following sub-categories:
- Geographic Markets
- By Segment
- Bisphosphonate Drugs
- SERM Drugs
- Parathyroid Hormone Drugs
- Calcitonin Drugs
- Denosumab Drugs
This section provides in-depth analysis of Osteoporosis Drugs Market size and
growth forecast for each drug category, driving factors and challenges
prevailing in the overall and at the micro market levels, and opportunities
and future outlook for all the levels.